Ospemifene

• CAT Number: A000148
• CAS Number: 128607-22-7
• Molecular Formula: C24H23ClO2
• Molecular Weight: 378.89
• Purity: ≥95%
• Synonyms: 128607-22-7; Osphena; FC-1271a; Deamino-hydroxytoremifene; Fc-1271
• Target: Estrogen Receptor/ERR
• Solubility: >15.4mg/mL in DMSO
• Storage: Store at -20°C
• InChI: 1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-
• InChIKey: LUMKNAVTFCDUIE-VHXPQNKSSA-N
• SMILES: C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)C3=CC=C(C=C3)OCCO)CCCl

Ospemifene is an oral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by /vulval and vaginal atrophy./ The medication was approved by the FDA in February 2013. (Source: http://en.wikipedia.org/wiki/Ospemifene)

Reference

1: Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV. Overall Safety of
Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
J Womens Health (Larchmt). 2017 Oct 24. doi: 10.1089/jwh.2017.6385. [Epub ahead
of print] PubMed PMID: 29064335.

2: Shin JJ, Kim SK, Lee JR, Suh CS. Ospemifene: A Novel Option for the Treatment
of Vulvovaginal Atrophy. J Menopausal Med. 2017 Aug;23(2):79-84. doi:
10.6118/jmm.2017.23.2.79. Epub 2017 Aug 31. Review. PubMed PMID: 28951854; PubMed
Central PMCID: PMC5606913.

3: Schiavi MC, Di Pinto A, Sciuga V, Faiano P, Di Tucci C, D/’oria O, Martoccia A,
Prata G, Carraro C, Ostuni R, Zullo MA, Muzii L, Benedetti Panici P. Prevention
of recurrent lower urinary tract infections in postmenopausal women with
genitourinary syndrome: outcome after 6 months of treatment with ospemifene.
Gynecol Endocrinol. 2017 Aug 30:1-4. doi: 10.1080/09513590.2017.1370645. [Epub
ahead of print] PubMed PMID: 28853624.

4: De Rosa N, Lavitola G, Giampaolino P, Morra I, Nappi C, Bifulco G. Impact of
Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical
Cancer: A Prospective Study. Biomed Res Int. 2017;2017:7513610. doi:
10.1155/2017/7513610. Epub 2017 Jul 11. PubMed PMID: 28781968; PubMed Central
PMCID: PMC5525090.

5: Alvisi S, Baldassarre M, Martelli V, Gava G, Seracchioli R, Meriggiola MC.
Effects of ospemifene on vaginal epithelium of post-menopausal women. Gynecol
Endocrinol. 2017 Dec;33(12):946-950. doi: 10.1080/09513590.2017.1332589. Epub
2017 May 31. PubMed PMID: 28562130.

6: Schiavi MC, Zullo MA, Faiano P, D/’Oria O, Prata G, Colagiovanni V, Giannini A,
Di Tucci C, Perniola G, Di Donato V, Monti M, Muzii L, Benedetti Panici P.
Retrospective analysis in 46 women with vulvovaginal atrophy treated with
ospemifene for 12 weeks: improvement in overactive bladder symptoms. Gynecol
Endocrinol. 2017 Dec;33(12):942-945. doi: 10.1080/09513590.2017.1323859. Epub
2017 May 11. PubMed PMID: 28490209.

7: Maldonado PA, Montoya TI, Acevedo JF, Keller PW, Word RA. Effects of vaginal
conjugated equine estrogens and ospemifene on the rat vaginal wall and lower
urinary tract. Biol Reprod. 2017 Jan 1;96(1):81-92. doi:
10.1095/biolreprod.116.144428. PubMed PMID: 28395337.

8: Bruyniks N, Biglia N, Palacios S, Mueck AO. Systematic indirect comparison of
ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric.
2017 Jun;20(3):195-204. doi: 10.1080/13697137.2017.1284780. Epub 2017 Mar 7.
PubMed PMID: 28267367.

9: Kubota R, Matsumoto S, Wajima T. Population pharmacokinetics of ospemifene and
safety evaluation of pharmacokinetic alterations caused by intrinsic and
extrinsic factors
. Int J Clin Pharmacol Ther. 2017 Apr;55(4):339-347. doi:
10.5414/CP202821. PubMed PMID: 28128722.

10: Kao CJ, Wurz GT, Lin YC, Vang DP, Phong B, DeGregorio MW. Repurposing
ospemifene for potentiating an antigen-specific immune response. Menopause. 2017
Apr;24(4):437-451. doi: 10.1097/GME.0000000000000776. PubMed PMID: 27922937;
PubMed Central PMCID: PMC5365365.